University of Chicago Medical Center Dept. of U. of Chicago Hosp(3) — Chicago, Illinois

University of Chicago Medical Center Dept. of U. of Chicago Hosp(3) is a clinical research site located in Chicago, Illinois, United States 60637.

Crixeo Health Trust Score: 61/100 (FAIR). This profile has not yet been claimed by the site owner.

University of Chicago Medical Center Dept. of U. of Chicago Hosp(3) has participated in 2 clinical trials.

Therapeutic areas: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 61/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Chicago Medical Center Dept. of U. of Chicago Hosp(3)?

University of Chicago Medical Center Dept. of U. of Chicago Hosp(3) has a Crixeo Trust Score of 61/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Chicago Medical Center Dept. of U. of Chicago Hosp(3) conducted?

University of Chicago Medical Center Dept. of U. of Chicago Hosp(3) has 2 clinical trials on record. Their work covers Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome.

Is University of Chicago Medical Center Dept. of U. of Chicago Hosp(3) accredited by Crixeo Health?

University of Chicago Medical Center Dept. of U. of Chicago Hosp(3) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Chicago Medical Center Dept. of U. of Chicago Hosp(3)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.